RAXORULIMOGENE BELZOVACIREPVEC
UNII P3D8R5LG7H

Substance Identification & Data

This profile provides standardized clinical and technical data for Raxorulimogene Belzovacirepvec, uniquely identified by the FDA Unique Ingredient Identifier (UNII) P3D8R5LG7H.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2648343-10-4 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code
P3D8R5LG7H
CAS Registry Number
2648343-10-4
RxNorm Concept ID
N/A

Detailed Substance Profile

Preferred Name
RAXORULIMOGENE BELZOVACIREPVEC
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
C203114
National Cancer Institute reference terminology for clinical and research data.
INN ID
12356
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
structurallyDiverse
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Raxorulimogene Belzovacirepvec. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

RAXORULIMOGENE BELZOVACIREPVEC

Common Names & Synonyms

RAXORULIMOGENE BELZOVACIREPVEC [INN]
RECOMBINANT REPLICATION-COMPETENT ONCOLYTIC VACCINIA VIRUS (VACV; STRAIN COPENHAGEN) ENCODING THREE CODON-OPTIMISED TRANSGENES: (I) ANTI-CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4 (CTLA-4) IMMUNOGLOBULIN G1 .GAMMA.1-CHAIN FUSED VIA A SYNTHETIC T2A PEPTIDE WITH HUMAN IMMUNOGLOBULIN KAPPA CHAIN (ANTI-CTL4 ANTIBODY) UNDER CONTROL OF THE VACV H5RMPROMOTER, (II) HUMAN FMS-LIKE RECEPTOR TYROSINE KINASE 3 LIGAND (FLT3L), ISOFORM X7, UNDER CONTROL OF THE VACV B19R PROMOTER, AND (III) MEMBRANE BOUND HUMAN INTERLEUKIN 12 SUBUNIT .ALPHA. (IL-12A, P35) UNDER CONTROL OF A SYNTHETIC VACV LATE PROMOTER (PLATE). THE VIRUS CARRIES MAJOR GENOMIC DELETIONS AT THE 5' END (COPMD5P) AND 3' END (COPMD3P) OF THE GENOME WITH THE ANTI-HCTLA-4 TRANSGENE INSERTED INTO THE COPMD5P REGION. IN ADDITION, INSERTION OF THE FLT3L AND IL-12P35 TRANSGENES LEADS TO DISRUPTION OF THE B8R LOCUS

External Clinical & Regulatory Resources

CAS
Common Chemistry
NCATS
Inxight Drugs
NLM
DailyMed Products
NCATS
GSRS Full Record
NIH
NCI Thesaurus